Skip to main content
A

Approxima

Approxima develops a novel percutaneous treatment system for patients suffering from tricuspid regurgitation. This technology targets the root cause of the pathology by employing a ventricular reshaping approach to reduce regurgitation. The system aims to provide a physiological-like repair via a short and straightforward implantation procedure.

Milan, ItalyFounded 2020131K+ followers
Updated 20 months ago

Funding

$1.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

PP
Funding rounds are not available yet.

Founders

Product

Problem

Tricuspid regurgitation (TR) affects over 13 million patients worldwide, with the majority of cases stemming from right ventricle dilation that causes papillary muscle dislodgement and leaflet tethering. Nearly all patients with TR are denied open-heart surgery due to the associated high mortality risk, leaving a significant unmet clinical need. The condition is associated with a 50% two-year mortality rate in severe cases.

Solution

Approxima is developing a percutaneous tricuspid valve repair system designed to address the root cause of tricuspid regurgitation through ventricular reshaping. The system employs a minimally invasive approach to reshape both the ventricle and annulus, offering a physiological-like treatment option. This technology aims to reduce tricuspid regurgitation and improve outcomes for patients at high risk for open-heart surgery. The implantation procedure is designed to be short and straightforward, with the technology protected by intellectual property in strategic geographies.

Target Audience

The primary target audience includes patients with at least moderate tricuspid regurgitation who are at high risk for open-heart surgery.

Features

  • Percutaneous tricuspid valve repair system based on a ventricular reshaping approach.
  • Designed to target the root cause of tricuspid regurgitation.
  • Aims for physiological-like treatment through ventricle and annulus reshaping.
  • Minimally invasive implantation procedure.
  • IP protected in strategic geographies.
This profile is AI-generated and may contain inaccuracies.